Study will examine safety, immune response, and dose of three promising immunogens
IAVI press release
IAVI, a global nonprofit scientific research organization, announces that the first doses of experimental HIV vaccine antigens were administered on December 15, 2025, at the Perinatal HIV Research Unit in Soweto, South Africa, initiating the IAVI G004 clinical trial. IAVI G004 is designed to advance the IAVI/Scripps Research strategy for HIV vaccine development. The hypothesis being tested is that highly specialized vaccine immunogens, delivered in a specific sequence, can target certain B cells within the immune system and coach them toward the production of broadly neutralizing antibodies against HIV. Scientists widely believe that a vaccine inducing broadly neutralizing antibodies could provide broad protection against many strains of HIV. Using three immunogens developed by IAVI/Scripps Research delivered on Moderna’s mRNA platform, this study will examine safety, immune responses, and dose levels.
Read the full press release here.
Source : IAVI
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.